Click For Photo: https://3c1703fe8d.site.internapcdn.net/newman/gfx/news/2019/22-scientistsde.jpg
Engineered T cell immunotherapy, such as chimeric antigen receptor T cell (CAR-T) and T cell receptor T cell (TCR-T) therapy, has emerged as a potent therapeutic strategy for treating tumors.
However, the genetic manipulation of primary T cells remains inefficient, especially during the clinical manufacturing process. There's an urgent need to develop a reliable method for the preparation of engineered T cells.
Research - Team - Prof - Cai - Lintao
A research team led by Prof. Cai Lintao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences and other collaborators developed a "safe, efficient and universal" technique based on bioorthogonal chemistry and glycol-metabolic labeling for viral-mediated engineered T cell manufacturing. Their findings were published in Advanced Functional Materials.
In this strategy, the functional azide motifs were anchored on T cell surfaces via the intrinsic glycometabolism of exogenous azide-glucose, thus serving as an artificial ligand for viral binding. The complementary functional moiety dibenzocyclooctyne (DBCO)/-conjugated PEI1.8K (PEI-DBCO) was coated on the lentiviral surface, which strengthened the virus-T cell interaction through DBCO/azide bioorthogonal chemistry.
Chemical - Receptor - Binding - T - Cells
"We found that this artificial chemical receptor effectively facilitated viral binding to T cells and elevated the transduction efficiency of the lentivirus from 20 percent to 80 percent without any effect on T cell proliferation and...
Wake Up To Breaking News!
Vote for gridlock, it's our only hope!